Literature DB >> 9498774

Redundancy of C/EBP alpha, -beta, and -delta in supporting the lipopolysaccharide-induced transcription of IL-6 and monocyte chemoattractant protein-1.

H M Hu1, M Baer, S C Williams, P F Johnson, R C Schwartz.   

Abstract

C/EBP alpha, -beta, and -delta are members of the CCAAT/enhancer binding protein family of transcriptional regulators. All three of these factors are expressed by bone marrow-derived macrophages, with the DNA binding activity of C/EBP beta and -delta increased by treatment with LPS while that of C/EBP alpha is decreased. We have ectopically expressed each C/EBP protein in P388 lymphoblasts. The expression of any of these transcription factors is sufficient to confer the LPS-inducible expression of IL-6 and monocyte chemoattractant protein-1 to lymphoblasts, which normally lack C/EBP factors and do not display LPS induction of proinflammatory cytokines. Thus, the activities of C/EBP alpha, -beta, and -delta are redundant in regard to the expression of IL-6 and monocyte chemoattractant protein-1. Since C/EBP beta-deficient mice have been reported to be largely normal in their expression of proinflammatory cytokines, it is likely that the lack of C/EBP beta is compensated for by the induction of C/EBP delta upon LPS treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Myeloid lineage switch of Pax5 mutant but not wild-type B cell progenitors by C/EBPalpha and GATA factors.

Authors:  Barry Heavey; Christoforos Charalambous; Cesar Cobaleda; Meinrad Busslinger
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

Review 2.  Transcriptional regulation of macrophage polarization: enabling diversity with identity.

Authors:  Toby Lawrence; Gioacchino Natoli
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

3.  Suppressor of cytokine signaling 3 inhibits LPS-induced IL-6 expression in osteoblasts by suppressing CCAAT/enhancer-binding protein {beta} activity.

Authors:  Chunguang Yan; Jay Cao; Min Wu; Wei Zhang; Tao Jiang; Aihiko Yoshimura; Hongwei Gao
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

Review 4.  CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection.

Authors:  Yujie Liu; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

5.  Critical role for CCAAT/enhancer-binding protein β in immune complex-induced acute lung injury.

Authors:  Chunguang Yan; Min Wu; Jay Cao; Huifang Tang; Mei Zhu; Peter F Johnson; Hongwei Gao
Journal:  J Immunol       Date:  2012-06-25       Impact factor: 5.422

Review 6.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

7.  C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.

Authors:  Estelle Duprez; Katharina Wagner; Heike Koch; Daniel G Tenen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

8.  CCAAT/enhancer-binding protein beta and delta binding to CIITA promoters is associated with the inhibition of CIITA expression in response to Mycobacterium tuberculosis 19-kDa lipoprotein.

Authors:  Meghan E Pennini; Yi Liu; Jianqi Yang; Colleen M Croniger; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

9.  Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein δ pathway.

Authors:  Chunguang Yan; Peter A Ward; Ximo Wang; Hongwei Gao
Journal:  FASEB J       Date:  2013-04-12       Impact factor: 5.191

10.  In vivo deficiency of both C/EBPβ and C/EBPε results in highly defective myeloid differentiation and lack of cytokine response.

Authors:  Tadayuki Akagi; Nils H Thoennissen; Ann George; Gay Crooks; Jee Hoon Song; Ryoko Okamoto; Daniel Nowak; Adrian F Gombart; H Phillip Koeffler
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.